Actavis announced the launch of Guanfacine HCl, the generic version of Shire’s Intuniv.
Intuniv is a central alpha-2A agonist indicated for attention deficit hyperactivity disorder (ADHD), as monotherapy or as adjunct to stimulant medications in patients aged 6–17. Guanfacine is not a central nervous system (CNS) stimulant. The mechanism of action of guanfacine in ADHD is not known.
RELATED: FDA Questions Therapeutic Equivalence of Two Generic ADHD Drugs
Guanfacine HCl is available as 1mg and 2mg strength tablets in 100-count bottles.
For more information call (800) 432-8534 or visit Actavis.US.
